Compare · TGEN vs TMO
TGEN vs TMO
Side-by-side comparison of Tecogen Inc. (TGEN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TGEN and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $255.19B, about 4914.8x TGEN ($51.9M).
- TMO has been more active in the news (9 items in the past 4 weeks vs 7 for TGEN).
- TMO has more recent analyst coverage (25 ratings vs 4 for TGEN).
- Company
- Tecogen Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $51.9M
- $255.19B
- 1M return
- -
- -0.77%
- 1Y return
- -
- +20.26%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- 2025
- News (4w)
- 7
- 9
- Recent ratings
- 4
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest TGEN
- Chief Financial Officer Roger P. Deschenes bought $17,997 worth of shares (10,000 units at $1.80), increasing direct ownership by 12% to 91,975 units (SEC Form 4)
- General Counsel & Secretary John Kimball Whiting IV bought $19,600 worth of shares (10,000 units at $1.96), increasing direct ownership by 24% to 51,954 units (SEC Form 4)
- Director Earl Lewis bought $19,557 worth of shares (10,000 units at $1.96), increasing direct ownership by 0.99% to 1,021,006 units (SEC Form 4)
- SEC Form 10-Q filed by Tecogen Inc.
- Tecogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Tecogen Reports Third Quarter 2026 Financial Results
- Tecogen Schedules Earnings Release Date and Conference Call for Q3 2026 Results
- Data Center Cuts Electric Bills Substantially with Tecogen's InVerde
- SEC Form 8-K filed by Tecogen Inc.
- Amendment: VP of Business Development Lafaille Stephen was granted 29,013 shares, increasing direct ownership by 234% to 41,389 units (SEC Form 4)
Latest TMO
- President & COO Pettiti Gianluca sold $2,898,969 worth of shares (4,133 units at $701.42) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 2% to 22,816 units (SEC Form 4)
- Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026
- Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
- Thermo Fisher Scientific Announces Quarterly Dividend
- SEC Form SCHEDULE 13G filed by Thermo Fisher Scientific Inc
- Director Sperling Scott M gifted 3,490 shares, decreasing direct ownership by 5% to 65,989 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. sold $1,999,960 worth of shares (2,831 units at $706.45) (SEC Form 4)
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- SEC Form 8-K filed by Thermo Fisher Scientific Inc